» Articles » PMID: 11079168

The Utility of Ki-ras Mutation Analysis in the Cytologic Diagnosis of Pancreatobiliary Neoplasma

Overview
Journal Cancer J
Specialty Oncology
Date 2000 Nov 18
PMID 11079168
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Mutations involved in neoplastic progression may be able to serve as markers for the presence of small numbers of neoplastic cells that would otherwise escape detection in diagnostic assays. Previous retrospective studies have suggested that the sensitivity of the cytologic diagnosis of pancreatic and biliary tract carcinomas is improved when analysis includes Ki-ras exon 1, which is commonly mutated in these neoplasms. We report our experience with the systematic prospective application of Ki-ras gene analysis to the evaluation of fine-needle aspirates and brushings from the pancreatobiliary tract.

Materials And Methods: Between September 1996 and April 1999, 75 pancreatic fine-needle aspirates and common bile duct brushings submitted for routine cytologic diagnosis were also evaluated for mutations in Ki-ras exon 1 by polymerase chain reaction/single-strand conformation polymorphism analysis. After routine preparation of the specimens, residual material was used for molecular analysis. Results are compared with the morphologic diagnosis and available clinical information.

Results: Single-strand conformation polymorphism mutation patterns in Ki-ras were detected in 22 of the 70 consecutive clinical specimens with adequate DNA and at least 6 months of available clinical follow-up. Sensitivity, specificity, and positive predictive value for the presence of concurrent or subsequent pancreatobiliary carcinoma were 33%, 97%, and 93%, respectively, for definitive cytologic diagnosis alone, and 53%, 97%, and 95% for positive Ki-ras single-strand conformation polymorphism mutation pattern alone. If definitive positive cytology or atypical/suspicious cytology with a positive Ki-ras single-strand conformation polymorphism mutation pattern is used, sensitivity is 55%, specificity is 97%, and positive predictive value is 96% for the presence of pancreatobiliary carcinoma.

Discussion: Results support the routine use of Ki-ras mutational analysis to increase the sensitivity of the cytologic evaluation of pancreatobiliary fine-needle aspirates and common bile duct brushings with atypical or suspicious morphology without compromising specificity.

Citing Articles

KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.

McHenry A, Rottmann D, Buza N, Hui P Virchows Arch. 2023; 483(1):71-79.

PMID: 37219599 DOI: 10.1007/s00428-023-03564-z.


Combining the amplification refractory mutation system and high-resolution melting analysis for KRAS mutation detection in clinical samples.

Oliveira B, Costa B, Morao B, Faias S, Veigas B, Pereira L Anal Bioanal Chem. 2023; 415(14):2849-2863.

PMID: 37097304 PMC: 10185647. DOI: 10.1007/s00216-023-04696-6.


KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.

Zuo T, Wong S, Buza N, Hui P Mod Pathol. 2017; 31(2):350-357.

PMID: 29027536 DOI: 10.1038/modpathol.2017.121.


Next generation sequencing improves the accuracy of KRAS mutation analysis in endoscopic ultrasound fine needle aspiration pancreatic lesions.

de Biase D, Visani M, Baccarini P, Polifemo A, Maimone A, Fornelli A PLoS One. 2014; 9(2):e87651.

PMID: 24504548 PMC: 3913642. DOI: 10.1371/journal.pone.0087651.